Annovis Bio, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 07X.F | VYGR | ALEC | LONA | ALGS | ABVC | |
|---|---|---|---|---|---|---|
| Market cap | 36.36M | 115.23M | 254.58M | 43.01M | 31.35M | 26.69M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.3 | -1.5 | -3.1 | — | -1.0 | -2.3 |
| Price/book | -9.6 | 0.7 | -25.6 | 1.3 | 1.0 | 2.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −44.39% | −55.69% | +75.38% | +13.84% | −29.30% | −64.79% |
| Today | −12.26% | +2.19% | +11.22% | −4.30% | +5.68% | +1.51% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 07X.F news ›Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE
MALVERN, Pa., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ('Annovis” or the 'Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative…
Annovis Bio, Inc. Promotes Cheng Fang as Chief Scientific Officer
Annovis Bio, Inc. announced the promotion of Cheng Fang, Ph.D., to Chief Scientific Officer, effective July 01, 2026. Dr. Fang joined Annovis in 2021 and most recently served as Senior Vice President,... announced the promotion of Cheng…
Annovis Bio, Inc. Announces Partnership With Weave Bio In Preparation Of NDA For Buntanetap In Alzheimer?s Disease
Annovis Bio, Inc. announced a collaboration with Weave Bio, an AI platform for regulatory content and knowledge management, in support of the planned New Drug Application for buntanetap. Under the... announced a collaboration with Weave…
Certain Common Stock of Annovis Bio, Inc. are subject to a Lock-Up Agreement Ending on 17-AUG-2026.
These Common Stock will be under lockup for 90 days starting from 19-MAY-2026 to... Certain Common Stock of Annovis Bio, Inc are subject to a Lock-Up Agreement Ending on 17-AUG-2026
Annovis Bio corrects 2025 audit fees to $415,000, total fees $515,000
TradingView Annovis Bio corrects 2025 audit fees to $415,000, total fees $515,000 Annovis Bio corrected audit fee disclosure, reporting $415,000 in 2025 audit fees and $515,000 total fees. - Filed Form 8-K to correct typographica
More from 1 other outlet
Roth Capital Initiates Annovis Bio at Buy With $8 Price Target
... Biotechnology & Medical Research Roth Capital Initiates Annovis Bio at Buy With $8 Price Target Published on 07/08/2026 at 08:08 am EDT
Annovis Bio, Inc.(NYSE: ANVS) added to Russell Microcap Index
Annovis Bio, Inc. added to Russell Microcap Index... Published on 06/29/2026 at 01:33 am EDT Annovis Bio, Inc.(NYSE:ANVS) added to Russell Microcap Index
Annovis Bio, Inc.: Relative Strength Chart - Stock NYSE
Compare Annovis Bio, Inc. with the company of your choice via a Relative Strength chart. Real-time ANVS price, NYSE stock exchange Relative Strength Chart Annovis Bio, Inc. Biotechnology & Medical Research All financial news and data…
Annovis Bio Completes Patient Enrollment for Phase 3 Study of Buntanetap in Alzheimer's Disease
Annovis Bio has completed patient enrollment for the phase 3 trial evaluating buntanetap in patients with early Alzheimer's disease, the company said Tuesday. The trial enrolled 850 patients... Biotechnology & Medical Research Annovis Bio…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com9
- manilatimes.net1
- stocktitan.net1
- tradingview.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 12 articles, not a forecast.